Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Analysts at HC Wainwright upped their Q1 2025 EPS estimates for Atossa Therapeutics in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.05) per share for the quarter, up from their previous forecast of ($0.07). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics’ Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.30) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at ($0.18) EPS.

Separately, Ascendiant Capital Markets boosted their price objective on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 9th.

Atossa Therapeutics Stock Down 0.3 %

Atossa Therapeutics stock opened at $0.70 on Friday. The stock has a market cap of $89.93 million, a price-to-earnings ratio of -3.16 and a beta of 1.20. The business has a 50-day simple moving average of $0.79 and a 200 day simple moving average of $1.10. Atossa Therapeutics has a 52 week low of $0.66 and a 52 week high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Institutional Investors Weigh In On Atossa Therapeutics

Several hedge funds have recently added to or reduced their stakes in ATOS. Two Sigma Advisers LP lifted its position in Atossa Therapeutics by 214.1% in the 4th quarter. Two Sigma Advisers LP now owns 42,400 shares of the company’s stock worth $40,000 after buying an additional 28,900 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Atossa Therapeutics during the fourth quarter worth approximately $28,000. Bank of America Corp DE lifted its holdings in shares of Atossa Therapeutics by 51.3% in the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock worth $105,000 after acquiring an additional 37,809 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Atossa Therapeutics by 7.5% in the 4th quarter. Northern Trust Corp now owns 1,025,724 shares of the company’s stock valued at $968,000 after purchasing an additional 71,525 shares in the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Atossa Therapeutics by 59.6% during the 4th quarter. XTX Topco Ltd now owns 79,176 shares of the company’s stock valued at $75,000 after purchasing an additional 29,560 shares during the last quarter. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.